SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pisters LL, Von Eschenbach AC, Scott SM et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997; 157: 9215
  • 2
    Ghafar MA, Johnson CW, De La Taille A et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001; 166: 13337
  • 3
    Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001; 165: 193741
  • 4
    Roach M III, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 96574
  • 5
    Cookson MS, Aus G, Burnett AL. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 5405
  • 6
    Wiegel T, Lohm G, Hocht S et al. Achieveing an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome – results of a retrospective study. Int J Radiat Oncol Biol Phys 2009; 73: 100916
  • 7
    Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys 2008; 72: 9729
  • 8
    De Meerleer G, Fonteyne V, Meersschout S et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol 2008; 89: 20513
  • 9
    Pisters LL, Leibovici D, Blute M et al. Locally recurrent prostate cancer after initial radiation therapy. A comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009; 182: 51725
  • 10
    Leibovici D, Spiess PE, Heller L, Rodriguez-Bigas M, Chang G, Pisters LL. Salvage surgery for locally recurrent prostate cancer after radiation therapy: trick of the trade. Urol Oncol 2008; 26: 916
  • 11
    Sanderson KM, Penson DF, Cai J et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006; 176: 202531
  • 12
    Izawa JI, Perrotte P, Greene GF et al. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 2001; 165: 86770
  • 13
    Izawa JI, Madsen LT, Scott SM et al. Slavage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002; 20: 266471
  • 14
    Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006; 15: 27580
  • 15
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus Statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 103541
  • 16
    Babaian RJ, Donnelly B, Bahn D et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180: 199304
  • 17
    Levy DA, Pisters LL, Jones JS. Primary cryoablation nadir PSA and biochemical failure rates. J Urol 2009; 182: 9317
  • 18
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol 2003; 21: 216372
  • 19
    Levy DA, Li J, Jones JS. Impact of disease burden on cryoablation PSA outcomes. Urology 2010; 75: 47881
  • 20
    Karakiewicz PI, Bhojani N, Capitanio U et al. External validation of the updated Partin tables in a cohort of North American men. J Urol 2008; 180: 898902
  • 21
    Bhojani N, Salomon L, Capitanio U et al. External validation of the updated Partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys 2009; 73: 34752
  • 22
    Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Characterization of biochemical recurrence after radical prostatectomy. Urol Int 2006; 77: 1304
  • 23
    Sengupta S, Christensen CM, Zinke H et al. Detectable prostate specific antigen 60 and 120 days following radical prostatectomy for prostate cancer. Natural history and prognostic significance. J Urol 2006; 176: 55963
  • 24
    Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D’Amico AV. Predictors of short postoperative prostate specific antigen doubling time for patients diagnosed during the PSA era. Urology 2005; 65: 52832
  • 25
    Teeter AE, Banez LL, Presti JC et al. What are factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol 2008; 180: 19804
  • 26
    Naselli A, Introini C, Andreatta R, Spina B, Truini M, Puppo P. Prognostic factors of persistently detectable PSA after radical prostatectomy. Int J Urol 2009; 16: 826